HOWL - Rasio utang marang kapitalisasi buku Werewolf Therapeutics Inc.

Logo korporat perusahaan werewolftx.com (HOWL)

Werewolf Therapeutics (HOWL) develops innovative cytokines using PREDATOR technology for the targeted destruction of tumors. This debt-to-market cap chart clearly demonstrates financial stability, where the value 0.00 captures the metric level. The current R&D stage, characterized by a lack of sales, increases research expenses. However, the fierce competition with pharma behemoths for scientific priority creates risks of devaluation for the startup's developments.

HOWL Werewolf Therapeutics Inc.: Rasio utang marang kapitalisasi buku ing interval 04.07.2022 - 27.10.2026
Produk dadi Werewolf Therapeutics Inc.

This indicator assesses the business's dependence on borrowed funds relative to the market value of its equity. By analyzing the total debt-to-market capitalization ratio on GURU.Markets, an investor can track credit load dynamics based on daily asset revaluations. The metric is calculated as the ratio of total liabilities to the company's current market value. For Werewolf Therapeutics (HOWL), this is critical, as financing the aggressive development of the PREDATOR platform requires a balance between debt and capitalization. The biotech's high scientific productivity must be supported by a sustainable resource structure.

Pesaing Werewolf Therapeutics

ImmunityBio, Inc. - Utang-utang marang kapitalisasi buku|immunocore.com - Utang marang nilai buku|JANX (Janux Therapeutics, Inc.) - Rasio utang marang kapitalisasi buku|RCUS: Utang-utang marang nilai buku|Zymeworks Corp (ZYME) - Rasio utang marang kapitalisasi buku|TNGX (Tango Therapeutics Corp) - Rasio utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku IOVA (Iovance Biotherapeutics)|Utang-utang marang nilai buku immatics.com|XNCR: Utang-utang marang kapitalisasi buku|Utang marang aset resik Compass Therapeutics Inc CMPX|REPL: Utang marang nilai buku|LYEL - Utang-utang marang nilai buku|Utang marang nilai buku Innate Pharma S.A. (IPHA)|PYXS - Rasio utang marang aset resik|cgen.com - Utang-utang marang kapitalisasi buku|IOBT (IO Biotech Inc) - Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku STRO|Utang marang nilai buku INKT|Rasio utang marang kapitalisasi buku IMMX (Immix Biopharma, Inc.)|Utang marang nilai buku ALX Oncology Holdings Inc. ALXO|Utang marang nilai buku CUE (Cue Biopharma, Inc.)|PDS Biotech - Utang-utang marang kapitalisasi buku|Sonnet BioTherapeutics Holdings Inc. (SONN) - Rasio utang marang kapitalisasi buku|MAIA: Rasio utang marang nilai buku|Rasio utang marang kapitalisasi buku LIMN|Utang-utang marang nilai buku LAVA Therapeutics|NextCure - Utang marang nilai buku|Utang marang aset resik Leap Tx (LPTX)|Utang marang nilai buku Intensity Therapeutics|Utang marang modal buku senseibio.com (SNSE)|Utang-utang marang kapitalisasi buku Theriva Biologics, Inc.|Rasio utang marang aset resik Gritstone bio Inc. GRTS|KA (Kineta) - Utang-utang marang kapitalisasi buku|NEXI: Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku turnstonebio.com TSBX|Vaccinex Inc (VCNX) - Rasio utang marang aset resik|HARP (Harpoon Therapeutics) - Utang-utang marang kapitalisasi buku